IMVT

39.41

0.10% 0.04

Handel nachbörslich: 39.41

Immunovant Inc (IMVT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IMVT? Forum Prognose

Schlusskurs vom Vortag:

$39.37

Offen:

$39.8

24-Stunden-Volumen:

727.07K

Relative Volume:

0.42

Marktkapitalisierung:

$8.09B

Einnahmen:

Nettoeinkommen (Verlust:

$-505.61M

KGV:

-14.23

EPS:

-2.7697

Netto-Cashflow:

$-407.32M

1W Leistung:

-2.11%

1M Leistung:

+3.11%

6M Leistung:

+51.52%

1J Leistung:

+115.12%

1-Tages-Spanne:

$38.70

$39.87

1-Wochen-Bereich:

$38.00

$41.21

52-Wochen-Spanne:

$14.32

$41.23

Immunovant Inc Stock (IMVT) Company Profile

Firmenname

Immunovant Inc

Sektor

Healthcare (1071)

Branche

Biotechnology (598)

Telefon

917-410-3120

Adresse

1000 PARK FORTY PLAZA, DURHAM, NY

Mitarbeiter

315

Twitter

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

IMVT's Discussions on Twitter

Compare IMVT vs VRTX, REGN, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IMVT Immunovant Inc	39.41	8.09B	0	-505.61M	-407.32M	-2.7697
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-20	Eingeleitet	Bernstein	Mkt Perform
2026-01-06	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-10-14	Eingeleitet	Truist	Hold
2025-07-10	Fortgesetzt	Goldman	Neutral
2025-03-03	Eingeleitet	Jefferies	Hold
2025-01-03	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-10-09	Bestätigt	Oppenheimer	Outperform
2024-03-28	Eingeleitet	Oppenheimer	Outperform
2024-03-13	Eingeleitet	Goldman	Buy
2024-02-20	Eingeleitet	JP Morgan	Overweight
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-10-13	Hochstufung	UBS	Neutral → Buy
2023-09-26	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-05-01	Eingeleitet	BofA Securities	Buy
2023-04-25	Eingeleitet	Citigroup	Buy
2023-03-31	Eingeleitet	Piper Sandler	Overweight
2023-03-30	Eingeleitet	Stifel	Buy
2023-02-15	Eingeleitet	Cantor Fitzgerald	Overweight
2023-02-13	Hochstufung	Guggenheim	Neutral → Buy
2023-01-03	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-09-26	Herabstufung	UBS	Buy → Neutral
2021-12-08	Eingeleitet	Wells Fargo	Equal Weight
2021-08-03	Herabstufung	Robert W. Baird	Outperform → Neutral
2021-08-02	Herabstufung	Credit Suisse	Neutral → Underperform
2021-06-01	Herabstufung	Guggenheim	Buy → Neutral
2021-06-01	Herabstufung	Stifel	Buy → Hold
2020-10-28	Eingeleitet	UBS	Buy
2020-10-12	Eingeleitet	Guggenheim	Buy
2020-10-08	Eingeleitet	Stifel	Buy
2020-10-02	Eingeleitet	Credit Suisse	Outperform
2020-08-26	Bestätigt	H.C. Wainwright	Buy
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-07-29	Eingeleitet	H.C. Wainwright	Buy
2020-02-24	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Immunovant Inc Aktie (IMVT) Neueste Nachrichten

Jul 25, 2026

Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com - Investing.com Nigeria

Jul 25, 2026

Jul 24, 2026

Immunovant director Atul Pande sells $59,699 in shares By Investing.com - Investing.com Canada

Jul 24, 2026

Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting - Kalkine Media

Jul 24, 2026

Jul 23, 2026

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - The Manila Times

Jul 23, 2026

Jul 22, 2026